Skip to contentA
Axim Biotechnologies, Inc.
A
AXIMAxim Biotechnologies, Inc. Q4 2016 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$12.21K$12.21Kderived−20.8% vs Q4 2015 Net Income-$1.18M-$1.18MderivedN/M vs Q4 2015 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Axim Biotechnologies, Inc. · CIK 1514946 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Gross Profitderived-$100,960N/M Operating Incomederived-$770,225N/M Operating Cash Flowderived-$532,447N/M Free Cash Flowderived-$532,447N/M Margins · derivedGross margin-826.7%−812.8 pt vs Q4 2015
Operating margin-6306.6%+34615.4 pt vs Q4 2015
Net margin-9691.2%+31311.9 pt vs Q4 2015
ended Dec 31, 2016 · filed Apr 17, 2017 · 107 d after period end